Notice of first launch, interruption or termination of supply of a human drug
 Date ▲HolderCodeDrugDate fromSubject
 8.2.2024Mylan Ireland Limited (MNY)3648ATramadol Mylan 200 mg (tbl plg 30x200 mg (blis.Al/PVC/PE/PVDC))19.2.2024R
 8.2.2024Mylan Pharmaceuticals Limited (MLB-IE-1)5222AMemantin Mylan 10 mg filmom obalené tablety (tbl flm 56x10 mg (blis.PVC/PVDC/Al))19.2.2024R
 8.2.2024Teva B.V. (TEV-NL-4)9388BTadalafil Teva 5 mg (tbl flm 28x5 mg (blis.PVC/PCTFE/Al))31.1.2022O
 8.2.2024G.L. Pharma GmbH (GLH-2)96305Neurotop retard 300 mg (tbl plg 50x300 mg (blis.PVC/PVDC/Al))7.2.2024R
 8.2.2024B.Braun Melsungen AG (BME)5718ARingerfundin (sol inf 10x1000 ml (fľ.PE))8.2.2024R
 8.2.2024Egis Pharmaceuticals PLC (EGI)14596Frontin 0,5 mg (tbl 30x0,5 mg (liek.skl.hnedá))8.2.2024O
 8.2.2024Egis Pharmaceuticals PLC (EGI)14598Frontin 1 mg (tbl 30x1 mg (liek.skl.hnedá))8.2.2024O
 7.2.2024Zentiva a.s. (ZNT-SK-2)44310RISENDROS 35 mg (tbl flm 12x35 mg (blis. OPA/Al/PVC/Al))8.2.2024R
 7.2.2024Zentiva, k.s. (ZNT-1)2148EAtominex 40 mg (cps dur 56x40 mg (blis.PVC/PVDC/Al))8.2.2024R
 7.2.2024Zentiva, k.s. (ZNT-1)6451ATezeo HCT 80 mg/25 mg (tbl 28x80 mg/25 mg (blis.OPA/Al/PVC/Al))8.2.2024R
 7.2.2024Baxalta Innovations GmbH (BXA)1889CCuvitru 200 mg/ml (sol inj 1x10 ml (liek.inj.skl.))7.2.2024R
 6.2.2024Aspen Pharma Trading Limited (ASE-1)97170Ovestin (crm vag 1x15 g (tuba Al+aplikátor))10.3.2024R
 6.2.2024Zentiva a.s. (ZNT-SK-2)36243CINIE 50 (tbl 6x50 mg (blis. OPA/Al/PVC/Al))7.2.2024O
 6.2.2024Zentiva, k.s. (ZNT-1)01076Ophthalmo-Framykoin (ung oph 1x5 g (tuba Al))6.2.2024R
 6.2.2024Zentiva, k.s. (ZNT-1)2529DDasatinib Zentiva 70 mg filmom obalené tablety (tbl flm 60x70 mg (blis.OPA/Al/PVC/Al))9.2.2024O

Subject means:
U-Placement of medicine to Slovakian market, R-Discontinuation of medicine supply to Slovakian market,
O-Resumption of medicine supply to Slovakian market, Z-Cancelation of medicine supply to Slovakian market


Date from
From
To



 
Processed by the system MCR.Prerusenie (8.0)